髓样分化因子88L265P突变在B细胞增殖性肿瘤中的研究进展  

Progress of myeioid differentiation factor 88 L265P mutation in B-cell proliferative neoplasms

作　　者：韩笑笑 程月新[1] 徐浩[1] Han Xiaoxiao;Cheng Yuexin;Xu Hao(Department of Hematology,Yancheng City No.1 People＂ s Hospital,the Fourth Affiliated Hospital of Nantong University,Yancheng Hospital Affiliated of Xuzhou Medical University,Yaucheng 224006,China)

机构地区：[1]江苏省盐城市第一人民医院南通大学第四附属医院徐州医科大学附属盐城医院血液科,江苏省224006

出　　处：《白血病．淋巴瘤》2018年第8期501-505,共5页Journal of Leukemia & Lymphoma

摘　　要：髓样分化因子88（MYD88）是Toll样受体（TLR）信号通路中的一个关键接头分子，在肿瘤的发生、发展中起重要作用。近期研究发现在90％的华氏巨球蛋白血症和约40％的弥漫大B细胞淋巴瘤等B细胞增殖性肿瘤患者中存在功能活化的MYD88L265P突变。由于B细胞增殖性肿瘤的不同类型都具有其独特的组织学形态、免疫组织化学、临床特点，因此MYD88L265P在各类型B细胞增殖性肿瘤中的突变率也有所不同。文章就MYD88L265P的突变在B细胞增殖性肿瘤中的研究进展进行综述。Myeloid differentiation factor 88 （MYD88） is a key linker in the Toil-like receptor （TLR） signaling pathway, which plays an important role in the progression of the tumour. Recent studies have shown that the activating mutation of MYD88 L265P has been identified in about of 90 % lymphoplasmacytic lymphoma/Waldenstrom ~ s macroglobulinemia and about of 40 % diffuse large B-cell lymphoma and other subtypes of B-cell proliferative neoplasms. Different types of B-cell proliferative neoplasms have their own histology, immunohistochemistry and clinical characteristics, thus, mutation rates of MYD88 L265P are different. This review discusses the latest progress of MYD88 L265P mutation in B-cell proliferative neoplasms.

关 键 词：MYD88 L265P突变 淋巴浆细胞淋巴瘤/Waldenstrom巨球蛋白血症 淋巴瘤 大 B一细胞 弥漫眭 白血病 淋巴细胞 慢性 B细胞 边缘区淋巴瘤 

分 类 号：R733.1[医药卫生—肿瘤]